Published in Gene Therapy Weekly, August 12th, 2004
According to a study from Belgium, "an in vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838, a phosphorothioate antisense oligonucleotide targeting human tumor necrosis factor alpha (TNF-alpha) mRNA, following multidose administration via intravenous and oral routes. Oral tablet formulations of ISIS 104838 were preformulated with the permeation enhancer sodium caprate in an enteric-coated solid dosage form."
"The average plasma bioavailability of ISIS 104838 was 1.4% relative to IV. The tissue distribution profile was similar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.